换一批Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
第一作者：
Robert,Roskoski
第一单位：
Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address: rrj@brimr.org.
作者：
关键词
Avapritinib (PubChem CID: 118023034)Fedratinib (PubChem CID: 16722836)Financial toxicityFostamatinib (PubChem CID: 11671467)Futibatinib (PubChem CID: 71621331)Health insuranceIbrutinib (PubChem CID: 24821094)Imatinib (PubChem CID: 5291)Lapatinib (PubChem CID: 208908)Nintedanib (PubChem CID: 135423438)Orphan drug designationOsimertinib (PubChem CID: 71496458)Out-of-pocket expensesPharmacy-benefit managersTucatinib (PubChem CID: 51039094)U.S. Inflation Reduction Act of 2022
DOI
10.1016/j.phrs.2023.107036
PMID
38096958
发布时间
2026-05-27
- 浏览0
Pharmacological research
107036页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
